{"organizations": [], "uuid": "571fbb805f79f82db5f5c4f828c3c96d576bff7f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-xultophy-approved-in-canada-for-tr/brief-xultophy-approved-in-canada-for-treatment-of-adults-with-type-2-diabetes-idUSFWN1RV0WC", "country": "US", "domain_rank": 408, "title": "BRIEF-Xultophy Approved In Canada For Treatment Of Adults With Type 2 Diabetes", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-18T22:05:00.000+03:00", "replies_count": 0, "uuid": "571fbb805f79f82db5f5c4f828c3c96d576bff7f"}, "author": "", "url": "https://www.reuters.com/article/brief-xultophy-approved-in-canada-for-tr/brief-xultophy-approved-in-canada-for-treatment-of-adults-with-type-2-diabetes-idUSFWN1RV0WC", "ord_in_thread": 0, "title": "BRIEF-Xultophy Approved In Canada For Treatment Of Adults With Type 2 Diabetes", "locations": [], "entities": {"persons": [], "locations": [{"name": "canada", "sentiment": "none"}, {"name": "canada", "sentiment": "none"}], "organizations": [{"name": "novo nordisk a/s", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 19 (Reuters) - Novo Nordisk A/S:\n* XULTOPHY APPROVED IN CANADA FOR THE TREATMENT OF ADULTS WITH TYPE 2 DIABETES Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-04-18T22:05:00.000+03:00", "crawled": "2018-04-18T22:21:10.001+03:00", "highlightTitle": ""}